Development of a Multi-Epitope Recombinant Protein for the Diagnosis of Human Visceral Leishmaniasis

Farnoosh JAMEIE 1, *Abdolhossein DALIMI 1, Majid PIRESTANI 1, Mehdi MOHEBALI 2

1. Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Received 21 Feb 2019
Accepted 10 May 2019

Abstract
Background: Iran is one of the endemic areas of Mediterranean Visceral Leishmaniasis, a disease caused by Leishmania infantum. In this work, we examined whether Proteína quimérica 10 (PQ10) recombinant protein is suitable for immunological diagnosis of human visceral leishmaniasis.

Methods: The study was carried out in Tarbiat Modares University during 2016-2018. The coding sequence of PQ10 recombinant protein was sub-cloned in pET28 expression vector and was commercially synthesized by GENERAY Biotechnology, China. Sequencing with proper primers was done, the expression, optimization of expression and protein purification were performed, and the purified recombinant protein was confirmed by western blot. The efficacy of PQ10 for serodiagnosis was evaluated with 50 positive and 50 negative serum samples, which confirmed by the direct agglutination test and collected from individuals living in the visceral leishmaniasis endemic areas of Iran. ELISA was performed with the PQ10 recombinant protein.

Results: The 95% CI sensitivity of ELISA that was evaluated with sera from naturally infected individuals was 84%. The 95% CI specificity value of the ELISA determined with sera from healthy individuals (50 serum samples) and from individuals with other infectious diseases was 82%. The 95% CI positive predictive value (PPV) and negative predictive value (NPV) were exterminated 82.35% and 83.67%, respectively.

Conclusion: We have used a recombinant synthetic protein to improve serodiagnosis of human visceral leishmaniasis. PQ10 could be useful for diagnosis of asymptomatic cases, as well as in the early phase of infections.
Introduction

Leishmaniasis is a majorly neglected tropical disease that its victims are among the poorest people that has been acknowledged by the WHO (1). While visceral leishmaniasis is endemic in northwestern and southern areas of the Iran, but the report of disease is sporadic and about 100–300 new cases reported annually (2).

The successful control of the disease requires efficient and reliable methods of diagnosis and for this purpose enormous efforts have been directed toward developing diagnostic tests (3). But current serodiagnostic techniques are not satisfactory because they do not discriminate between disease and asymptomatic infection (4). For example, immunological assays such as ELISA and indirect immunofluorescence assay (IFA) offer moderate sensitivity and specificity or as for direct agglutination test (DAT), cost, multiple steps, incubation, and antigenic variations are the limiting factors (5), thus leading to the misdiagnosis of infected animals cases in endemic areas (6).

In recent studies, different numbers of Leishmania antigens have been investigated for serodiagnostic purposes (7–11). The direct agglutination test and rk39 dipstick have made a progress in detecting visceral leishmaniasis. Some other kinesin-related protein, including K26, K28, and KE16 provided promisingly diagnostic accuracy in the diagnosis of visceral leishmaniasis (12), but despite these promising results, tests with other multiepitope proteins, especially antigens that could be used to detect visceral leishmaniasis in an early phase, are still needed in human with different clinical status to follow up of human infection. High sensitivities and specificities in these tests can be achieved by using multiepitope proteins, which have been shown to be a valuable tool in canine visceral leishmaniasis diagnosis (13).

A multiepitope recombinant protein (PQ10=Proteína Quimérica10 or Chimeric Protein10), a protein that consisted of ten antigenic peptides, showed good results in diagnosis of canine visceral leishmaniasis by ELISA, with accuracy of up to 0.94 (13,14).

The present study was carried out to develop and evaluate PQ10 in detecting human visceral leishmaniasis in the early phase.

Materials and Methods

Human sera collecting

The present study was carried out in the Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran during 2016-2018. Human sera that were confirmed as positive by the direct agglutination test (DAT) for visceral leishmaniasis were prepared as follows: for asymptomatic serum samples (Group A, n=25), blood was taken from apparently healthy blood donors (that were found positive for visceral leishmaniasis) from six blood service centers in Ardabil Province, where visceral leishmaniasis cases had been recorded.

The human symptomatic serum samples (Group B, n=25) had been collected during the time in the Parasitology Laboratory, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Human sera confirmed as negative for visceral leishmaniasis prepared as follows: 50 serum samples were collected from healthy individuals who were residents in visceral leishmaniasis endemic areas in Iran (group C). These negative sera were used to define a cut off value. Moreover, 20 serum samples were collected from patients with other infectious diseases (Toxoplasmosis (4 sample), bartonellosis (2 sample), echinococcosis (1 sample), syphilis (1 sample), strongyloidiasis (1 sample), malaria infection (2 sample), cytomegalovirus infection (2 sample), fasciolosis (1 sample), trichostrongylosis (1 sample), tuberculosis (1 sample), measles (2 sample), hymenolepiasis (1 sample) and toxo-
cariasis (1 sample) who were residing in non-
Leishmania endemic areas in Iran (group D).
Thirty of the negative samples and twenty of
the serum samples from patients with other
infectious disease were used to calculate speci-
ficity. All negative samples were confirmed for
absence of anti-Leishmania antibodies by DAT.

**Design of synthetic gene constructs**

The PQ10 multiepitope synthetic gene was
designed according to Faria et al (13). First, 10
coding sequences of antigenic peptides (8)
were joined, resulting in PQ10. A flexible link-
er (Gly-Ser-Gly-Ser-Gly) coding sequence was
used as a spacer between epitope sequences
(15). NdeI and NotI restriction sites were
added to the 5' and 3' ends, respectively, of
the synthetic gene to aid in cloning. For affini-
ity purification of recombinant protein, a
6xHIS tag coding sequence was added up-
stream of the stop codon of the synthetic gene.
The sequence was codon-optimized for
Esche-
richia coli expression. The PQ10 gene was
commercially synthesized by GENERAY Bio-
technology, China. A synthetic gene was
cloned into the NdeI and NotI restriction sites
of a pET28 expression vector, resulting in
pET-PQ10. Sequence analyses of the cloned
fragments were done for confirmation of the
correct fusion and the orientation of the insert.

**Expression, production, purification and confirmation of recombinant protein**

Recombinant plasmid was transformed to
E.coli BL21 DE3 expression host and protein
expression was carried out by inoculating 500
ml of Luria Bertani medium containing 0.05
mg/ml kanamycin with an overnight bacterial
culture. All cultures were incubated on a rota-
ry shaker at 180 rpm at 37 °C. Cultures were
grown until an optical density of 0.6 at 600 nm
was attained. Then, the expression of PQ10
recombinant protein was induced by adding 1
mM of IPTG (isopropyl-Beta-D-
thiogalactopyranoside) to the medium on a
rotary shaker (180 rpm) at 37 °C. Induction
time was 5 h, the expression levels were as-
sessed at one-h intervals of induction. Induced
samples (soluble and insoluble protein) were
screened and analyzed by SDS-PAGE
(mod.VSTS-3000; AKHTARIAN) with 12.5%
resolving gel, followed by Coomassie Brilliant
Blue G-250 staining. Cultures (200 ml of 4-h
induced) were pelleted and purification of
PQ10 protein was performed under denatur-
ing conditions, according to the manufactur-
er's instructions (The QL-A expressionist TM,
QIAGEN). The eluted proteins were analyzed
by SDS-PAGE and were quantified using
Bradford method. Western blot analysis was
performed on purified protein samples. Prote-
ins were electrotransferred to nitrocellulose
membranes (Sigma-Aldrich®) in a semi-
dry transfer cell at 15 volts/overnight (mod WB-
1100, AKHTARIAN). Detection of antigens
was performed by an indirect antibody immu-
noassay using anti-human IgG (whole mole-
cule)-HRP (from rabbit) (Riz Pad tan Parse)
diluted 1:7000 in PBS with 0.05% Tween20 and
DAB staining.

**Checkerboard titration**

The best concentrations of the antigen, sera
and conjugates were optimized for the immu-
noassay by checkerboard titration. The micro-
plate was coated with antigen at concentra-
tions of 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32
and 64 µg/ml. These plates were incubated
with pools of sera from humans infected and
uninfected with L.infantum in different dilu-
tions (1:50, 1:100, 1:200, 1:400, 1:800, 1:1600,
1:3200). Binding of the antibodies was detec-
ted using anti-human IgG-HRP (from goat)
(Sigma, reference A8667) in different dilutions
(1:15000, 1:30000, 1:45000).

**Immunoassays with human sera**

ELISA procedures were done to evaluate the
antigenicity of multiepitope PQ10 protein.
Maxisorp microplate (Nunc, Denmark) was
coated overnight with 16 µg/ml PQ10 protein
diluted in 0.1 M carbonate buffer (pH 9.6) at 4
°C. After three washes with PBS-0.05%
Tween-20 (PBST) (PBS; 10.14 mM Na2HPO4;
1.37 mMKH₂PO₄; 146 mM NaCl; 2.64 mM KCl, pH 7.4, containing 0.05% Tween 20), wells were blocked with 200 μl/well of 1% Bovine Serum Albumin (BSA) in PBS at 37 °C for 2 h. Serum samples, diluted 1:100 in PBS-0.05% Tween-20 containing 0.5% BSA, were added and incubated at 37 °C for 1 h. After three washes, microplate was incubated with anti-human IgG-HRP (from goat) (Sigma, reference A8667), diluted 1:30000 in PBS at 37 °C for 1 h. After washing five times, reactions were developed with Tetra Methyl Benzidine (TMB) (Biolegend, reference 421101) and the microplates were incubated for 20 min in the dark room. Reactions were stopped with 2M H₂SO₄, and microplate was read at 450 nm in a DYNEX (MRX II) ELISA reader.

**Direct Agglutination Test (DAT) assay**

The principal procedures for preparing the DAT antigen were performed according to the previous researches (16,17). To perform the test, sera were screened by 1:800 dilution. The samples with titers 1:800 were diluted further to give end-point titers of 1:102400. Antigen control well (antigen only), in addition to negative and positive control sera (the positive serum was prepared from VL patients with *L. infantum* infection from the endemic areas confirmed by microscopy, culture and DAT titers of 1:102400) were used in all procedures. The highest dilution which agglutination was still visible, compared with negative control wells which had clear blue dots was considered as the cut off titer (17).

**Ethics Statement**

During the sample collection, informed consents had been obtained from all participants and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The project was approved by the Ethical Committee of Tarbiat Modares University with code No. IR.TMU.REC.1394.241, based on the Specific National Ethical Guidelines for Biomedical Research issued by the Research and Technology Depu-
yty of Ministry of Health and Medicinal Education of Iran.

**Statistical analysis**

The cut-off value of PQ10 protein was calculated as the mean values + 3SD of OD value of the negative sera that were obtained from healthy individuals. Consequently, OD values higher than the mean value + 3 SD+10% were considered as positive. The sensitivity, specificity, PPV and NPV were calculated as follows: Sensitivity = TP / (TP + FN) × 100%, specificity = TN / (TN + FP) × 100%, PPV = TP / (TP + FP) × 100%, NPV = TN / (TN + FN) × 100% (18). The kappa index (which is used to find the level of agreement of PQ10 antigen with DAT), the Youden's index (which is a single statistic that captures the performance of a dichotomous diagnostic test) and the McNemar test were calculated. Statistics were performed using SPSS(Chicago, IL, USA) version 16 and the differences between the results of PQ10-ELISA and DAT tests were considered statistically significant when P < 0.05.

**Results**

**Constructing molecular sequences, recombinant protein expression and confirmation of protein production**

A sequence that was codon-optimized (13) for PQ10 protein expression in *Escherichia coli* was commercially synthesized successfully (Fig. 1) and confirmed by sequencing with PET-28 vector specific primers.
The PQ10 multiepitope protein was successfully expressed by E.coli BL21 DE3 strain under the conditions described in methods.

Three-dimensional structure of PQ10 protein designed by I-TASSER server are shown in Fig. 2.

SDS-PAGE analysis of E. coli BL21 (DE3), which was transformed with pET28- PQ10 and induced with IPTG, showed the expected 21.4 kDa band of PQ10 protein. Fig. 3 shows the expression of PQ10 induced by IPTG 1 mM in different times. There was a difference in quantitative expression of protein among 1- to 5 h induced cells. The maximized protein expression was after 4 h after cells induced. PQ10 recombinant protein was found mainly in the insoluble fraction of the cell lysate. Fig. 3 shows PQ10 protein in cell lysate and its
purified form at the expected sizes (21.4 kDa). Concentration of the purified PQ10 protein was calculated as 150 μg/ml by the Bradford assay.

**Fig. 3:** Cell lysate fractions from IPTG-induced bacterial cultures in different times (A), T0: Non-induced BL21-pET28-PQ10; T1: 1-h induced BL21-pET28-PQ10; T2: 2-h induced BL21-pET28-PQ10; T3: 3-h induced BL21-pET28-PQ10; T4: 4-h induced BL21-pET28-PQ10; T5: 5-h induced BL21-pET28-PQ10 and BL21-pET28 as negative control and purified PQ10 protein (B), showing bands in the expected size (21.4 kDa) for the PQ10 recombinant protein. 12% SDS-PAGE gel stained with Coomassie blue-stained. M: molecular weight marker in kDa

Western blotting was used to examine affinity of purified PQ10 protein against the patient’s sera. Western blots of purified PQ10 demonstrated that recombinant protein reacted with the patient’s sera (Fig. 4).

**Fig. 4:** Nitrocellulose membrane after western blotting with anti-human IgG. M: Molecular marker in kDa

Available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)
**Immunoassays with human sera**

**Checkerboard titration**

The standardization assay performed to determine the best concentration of the PQ10, as well as the best dilutions of the primary and secondary antibodies. It was observed that the best results were obtained by coating the wells with the PQ10 recombinant protein at 16 µg/ml concentration, with the human sera diluted at 1:100 and the conjugate diluted at 1:30000.

**Sensitivity and specificity determination of PQ10-Indirect ELISA**

According to Table 1, 16% (8 samples) out of 50 confirmed subjects, who were infected by *L. infantum*, did not react with PQ10 antigen and 18% (9 samples) out of 50 healthy subjects reacted with PQ10. The PQ10 showed reactivity with 2 samples from healthy sera and cross reaction was observed in 7 of samples collected from other infectious diseases. The results of antibody detection by DAT and PQ10-Indirect ELISA testing are compared in Table 1.

**Table 1**: The diagnostic performance of anti-PQ10 indirect ELISA assay and comparison between ELISA using recombinant protein PQ10 (cut-off=0.555) and DAT result

<table>
<thead>
<tr>
<th></th>
<th>Positive ELISA result</th>
<th>Negative ELISA result</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Percentage</td>
<td>Number</td>
</tr>
<tr>
<td>DAT sera</td>
<td>Positive</td>
<td>42</td>
<td>84*</td>
</tr>
<tr>
<td>DAT sera</td>
<td>Negative</td>
<td>9</td>
<td>18</td>
</tr>
</tbody>
</table>

With the 95% CI, the PQ10-Indirect ELISA test was sensitive (84%) and specific (82%) for the diagnosis of visceral leishmaniasis, with a PPV and an NPV of 82.35 and 83.67%, respectively. Additionally, PQ10 multiepitope protein was able to detect 92% of asymptomatic and 76% of symptomatic infected human, which was confirmed with DAT. From 20 serum samples that were collected from patients with other infectious disease, seven samples from patients with Toxoplasmosis, Syphilis, Malaria infection, Cytomegalovirus infection, Tuberculosis, Measles and Hymenolepiasis were false positive. The kappa index was calculated 0.660 that showed good agreement with DAT. The Youden J index for PQ10-ELISA test was calculated 0.66. The McNemar test result was calculated 1 that indicated with 95% confidence interval, there is no significant difference between the results of DAT and PQ10-ELISA in the diagnosis of people that with infected with *L. infantum*.

**Discussion**

Visceral leishmaniasis has common clinical features with other commonly occurring diseases of human such as malaria, typhoid, and tuberculosis, thus its diagnosis is complex (5). As because the most of the antileishmanial drugs are toxic, ideally, a diagnostic test should make the distinction between acute disease and asymptomatic infection (19).

The current methods that are used for diagnosis of visceral leishmaniasis are splenic aspiration, in vitro culture of bone marrow and direct observation, but unfortunately these
methods are time consuming, invasive, life threatening, and are unable to detect the infected asymptomatic persons who may serve as a reservoir of VL (20). Diagnostic methods based on molecular tools such as PCR and real-time PCR have some disadvantages like being too cumbersome to perform and high cost (21).

The immunodiagnosis assays have become important alternatives for the above tests (19,22) and several different Leishmania antigens have been identified and characterized that has been used for the development of new enzymatic immunoassays (13). The number of false-positives will be increased when only one antigen is used in screening and confirmation diagnostic tests of VL (23). But, we have produced a multiepitope recombinant antigen, which is low cost in preparation, easy automation in ELISA tests and have high ability to detect circulating antibodies in the early phase of infection, according to previous researches (13).

ELISA has been used as an appropriate diagnostic method for almost all infectious diseases, including leishmaniasis (5) and this technique requires a highly specific antigen in order to capture a specific antibody; therefore, several antigenic molecules, such as surface antigens, ribosomal or nuclear proteins, histones and kinesin-related proteins were used for this purpose (24). The sensitivity and specificity of crude soluble antigen (CSA), that is one of the most commonly used antigens, ranges from 80 to 100% and 84 to 95%, respectively, but cross-reactivity among patients with tuberculosis, trypanosomiasis and toxoplasmosis has also been reported (5,22).

rK39 among the recombinant proteins, was the most successful antigen, which has good efficacy to detect active canine visceral leishmaniasis. The rK39 showed high sensitivity (90% ±100%) in detecting the disease from the Mediterranean basin and South America, but it has less sensitivity and specificity for detecting asymptomatic canine visceral leishmaniasis (25–31). rKLO8 and rK26 are other antigens that it is shown to be able to enhance the diagnostic accuracy of canine visceral leishmaniasis. The individual use of these two antigens indicated lower sensitivity and specificity (rKLO8, 68% and 92%, respectively; rK26, 77% and 91%, respectively) compared to their combination which exhibited higher sensitivity (85%) and specificity (93%) (32).

In some studies, the chimeric proteins has been used for diagnosis of L. infantum, with 79% sensitivity and 96% specificity in infected (n =59) and uninfected dogs (n= 15) respectively. In another study on 232 animals infected with Leishmania that had been confirmed by parasitological examination or RIFI method, the sensitivity and specificity of their chimeric antigen in diagnosis of visceral leishmaniasis were 96% and 99%, respectively (33,34).

In our study, the cut off value was calculated by adding three standard deviation values to the mean absorbance of 50 negative serum samples from healthy individuals. It provided values of 84% and 82% from sensitivity and specificity, respectively. The observation of false positives related to the cross-reaction samples (seven samples from patients with toxoplasmosis, syphilis, malaria infection, cytomegalovirus infection, tuberculosis, measles and hynemoliasis) raises the suspicion of cross-reaction with other infectious diseases. PQ10 multiepitope protein was able to detect 92% of asymptomatic infected human that is its advantage in performing control programs.

In research conducted with recombinant proteins usually a concentration less than 5 µg/ml was used in ELISA, but in this study, the 16µg/ml concentration of PQ10 recombinant protein was shown to be the best.

**Conclusion**

We have used a recombinant synthetic protein to improve human visceral leishmaniasis serodiagnosis. PQ10 could be used as a good antigen for diagnosing asymptomatic cases, as well as in the early phase of the infections.

Available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)
Acknowledgements

The present work is part of PhD. thesis, supported financially by Faculty of Medical Sciences Tarbiat Modares University (Grant No. 52.112071).

Conflict of interest

The authors declare that there is no conflict of interest.

References


Available at: http://ijpa.tums.ac.ir

Available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)